Seebacher V, et al. - Researchers retrospectively evaluated data of 116 patients with recurrent cervical cancer in whom serologic biomarkers had been assessed at the time of relapse, to determine the value of the Glasgow Prognostic Score (GPS) as a prognostic tool for predicting post-relapse survival (PRS) in patients with recurrent cervical cancer. Analysis revealed a 5-year PRS rate of 25% (SE 4.7%) after a median follow-up of 20.9 months from recurrence. Recurrence was limited to the pelvis in only 29.8% of the patients. Higher squamous cell carcinoma antigen levels, shorter median PRS, and less intensive treatment for relapse were correlated with the GPS. Patients with recurrent cervical cancer had shorter PRS in independent correlation with a higher GPS at the time of relapse, a history of radiation therapy, and the presence of peritoneal carcinomatosis or multiple sites of relapse.